Abstract
Multisite artery disease (MSAD) affects 15% to 30% of patients with clinically manifest atherosclerosis, and has a relevant negative impact on prognosis. However, studies specifically focused on MSAD are very few, and available evidence is scarce. Importantly, patients with MSAD require an integrated management, possibly by a "Vascular Team" composed of the different specialists involved in the treatment of atherosclerosis. A multi-disciplinary, patient-centered approach is mandatory to deal with the variety of clinical scenarios and comorbidities found in MSAD patients. The risk/benefit ratio for multi-site arterial revascularization should always be carefully assessed in MSAD patients, taking into account the additional risks of interventions in this subset of patients. Many therapeutic options have been proposed for multisite revascularization, but little evidence is currently available to support specific recommendations. Percutaneous revascularization of the different arterial districts, when feasible, appears promising because of the lower operative morbidity and mortality.
Keywords: Multisite artery disease, atherosclerosis, carotid artery stenosis, coronary artery disease, lower extremity artery disease, revascularization, carotid artery stenting, carotid endarterectomy, coronary artery bypass grafting, percutaneous coronary intervention, peripheral angioplasty, peripheral artery bypass, multi-disciplinary, guidelines, vascular team
Current Vascular Pharmacology
Title:Management of Patients with Poly-Vascular Disease: Priorities for Revascularization Procedures
Volume: 10 Issue: 6
Author(s): Marco De Carlo and Leonardo Misuraca
Affiliation:
Keywords: Multisite artery disease, atherosclerosis, carotid artery stenosis, coronary artery disease, lower extremity artery disease, revascularization, carotid artery stenting, carotid endarterectomy, coronary artery bypass grafting, percutaneous coronary intervention, peripheral angioplasty, peripheral artery bypass, multi-disciplinary, guidelines, vascular team
Abstract: Multisite artery disease (MSAD) affects 15% to 30% of patients with clinically manifest atherosclerosis, and has a relevant negative impact on prognosis. However, studies specifically focused on MSAD are very few, and available evidence is scarce. Importantly, patients with MSAD require an integrated management, possibly by a "Vascular Team" composed of the different specialists involved in the treatment of atherosclerosis. A multi-disciplinary, patient-centered approach is mandatory to deal with the variety of clinical scenarios and comorbidities found in MSAD patients. The risk/benefit ratio for multi-site arterial revascularization should always be carefully assessed in MSAD patients, taking into account the additional risks of interventions in this subset of patients. Many therapeutic options have been proposed for multisite revascularization, but little evidence is currently available to support specific recommendations. Percutaneous revascularization of the different arterial districts, when feasible, appears promising because of the lower operative morbidity and mortality.
Export Options
About this article
Cite this article as:
De Carlo Marco and Misuraca Leonardo, Management of Patients with Poly-Vascular Disease: Priorities for Revascularization Procedures, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520855
DOI https://dx.doi.org/10.2174/157016112803520855 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Strategies in Therapeutic Applications of Toxoplasmosis: Recent Advances in Liposomal Vaccine Delivery Systems
Current Drug Targets Pharmacological Treatment of Obesity, Food Intake, and Reversal of Metabolic Disorders
Current Nutrition & Food Science Peroxynitrite-Driven Mechanisms in Diabetes and Insulin Resistance – the Latest Advances
Current Medicinal Chemistry Biomedical Nano Tools: A Potential New Paradigm for Immunoassays and Immune Detection
Current Nanomedicine Ethnicity and Inflammatory Pathways - Implications for Vascular Disease, Vascular Risk and Therapeutic Intervention
Current Medicinal Chemistry Inflammaging and Proteases in Abdominal Aortic Aneurysm
Current Vascular Pharmacology Pharmacotherapy Before and After Endovascular Repair of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Sitosterolemia: Diagnosis, Metabolic and Hematological Abnormalities, Cardiovascular Disease and Management
Current Medicinal Chemistry Neutrophil Derived Microvesicles: Emerging Role of a Key Mediator to the Immune Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine SIRT1 as a Novel Potential Treatment Target for Vascular Aging and Age-Related Vascular Diseases
Current Molecular Medicine Growth Arrest Specific Gene (GAS) 6 Modulates Platelet Thrombus Formation and Vascular Wall Homeostasis and Represents an Attractive Drug Target
Current Pharmaceutical Design Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design HDL Therapy for the Treatment of Cardiovascular Diseases
Current Vascular Pharmacology New Challenges for ACE-Inhibitors in Vascular Diseases
Drug Design Reviews - Online (Discontinued) Protein Kinase C Isoforms - Implications to Thrombosis
Current Signal Transduction Therapy Isolated Systolic Hypertension: Epidemiology, Pathogenesis and Treatment
Current Hypertension Reviews Gold Salts Therapy in Respiratory Diseases
Current Respiratory Medicine Reviews Management of Prehypertension: Current Status and Future Strategies
Current Hypertension Reviews Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews